Holland Protonen Therapie Centrum

At Holland Protonen Therapie Centrum in Delft, the clinical research focus includes oesophageal cancer and oesophagogastric junction cancer, with a strong emphasis on treatment strategies for HER2 positive esophageal adenocarcinoma. The trials are designed to assess whether new combinations of therapy can improve survival and strengthen disease control for patients with these challenging cancers.

• Evaluating the benefit of adding targeted treatment to standard care for resectable HER2 positive esophageal adenocarcinoma
• Studying outcomes in oesophageal cancer and oesophagogastric junction cancer through more intensive treatment approaches
• Focusing on better survival results and longer-lasting control of digestive system tumors

This research combines therapeutic techniques and equipment with oncology care, reflecting a broader effort to improve how treatment is delivered and how effectively it works for people with upper gastrointestinal cancers.

The site is also involved in research on treatment optimization, where clinical trials examine how to improve the effectiveness of current cancer therapy rather than simply introducing new drugs. This includes studying whether more comprehensive treatment plans can lead to better long-term outcomes for patients with locally advanced disease.

• Assessing progression-free survival after total neoadjuvant treatment for node-positive oesophageal adenocarcinoma
• Comparing treatment strategies to determine which approach offers stronger disease control in oesophagogastric junction cancer
• Supporting research into more precise and effective care for patients treated at the Holland Protonen Therapie Centrum

Overall, the trials at this center are centered on improving diagnostics, refining therapeutics, and advancing care for cancers of the esophagus and nearby digestive tract.